BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 15462689)

  • 1. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials.
    Bertrand ME
    Curr Med Res Opin; 2004 Oct; 20(10):1559-69. PubMed ID: 15462689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
    Boos CJ
    Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease.
    Brugts JJ; Ferrari R; Simoons ML
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):345-60. PubMed ID: 19379059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D
    Acta Med Croatica; 2004; 58(2):129-34. PubMed ID: 15208798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
    Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
    Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ACE inhibition on neurohormones.
    Remme WJ
    Eur Heart J; 1998 Sep; 19 Suppl J():J16-23. PubMed ID: 9796836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
    Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
    Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S;
    Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
    Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for benefits of perindopril in hypertension and its complications.
    Laurent S
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
    Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
    Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.